Cargando…
Schiff base derived from thiosemicarbazone and anthracene showed high potential in overcoming multidrug resistance in vitro with low drug resistance index
Multidrug resistance (MDR) is a huge obstacle in cancer chemotherapeutics. Overcoming MDR is a great challenge for anticancer drug discovery. Here, DNA binding and cytotoxicity of Schiff base L1 and L2 were explored to assess their efficiency in fighting cancer and overcoming the MDR. L1 and L2 coul...
Autores principales: | Bai, Jie, Wang, Rui-Hui, Qiao, Yan, Wang, Aidong, Fang, Chen-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546733/ https://www.ncbi.nlm.nih.gov/pubmed/28814831 http://dx.doi.org/10.2147/DDDT.S138371 |
Ejemplares similares
-
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance
por: Pósa, Vivien, et al.
Publicado: (2022) -
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
por: Xue, Xue, et al.
Publicado: (2012) -
Biomolecular Interactions of Cytotoxic Ruthenium Compounds with Thiosemicarbazone or Benzothiazole Schiff Base Chelates
por: Maikoo, Sanam, et al.
Publicado: (2022) -
Synthesis and Biological Evaluation of New Thiosemicarbazone Derivative Schiff Bases as Monoamine Oxidase Inhibitory Agents
por: Çavuşoğlu, Betül Kaya, et al.
Publicado: (2017) -
Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance
por: Zhou, Lei, et al.
Publicado: (2018)